.Background: We explored the expression of Fatty Acid Synthase (FAS) in lung carcinomas and its association with clinico-pathological features and prognosis. FAS is a recently discovered molecule involved in the energy supply of normal cells. FAS is also overexpressed in neoplastic tissues because of their increased necessity for energy. Patients and Methods: One hundred and six patients with non-small cell lung carcinoma were followed-up for an average period of 5 years. FAS expression was detected immunohistochemically. Results: FAS staining was observed in 61 out of 106 cases (57.54%). Statistical analysis revealed that FAS had an overall low prognostic value (p=0.14), while FAS-negative expression in stage I patients showed a trend for better survival (p=0.10). PTNM stage (p0.0001) was the only significant prognostic marker for overall survival. Conclusion: FAS is a reliable marker of low-stage clinically aggressive lung carcinomas. The determination of FAS expression in lung carcinomas may stratify patients and determine therapeutic approaches for their care. Note .
Fatty Acid Synthase (FAS) is a Marker of Increased Risk of Recurrence in Lung Carcinoma / Visca, P; Sebastiani, V; Botti, C; Diodoro, Mg; Pasquali, Lr; Romagnoli, F; Brenna, A; Alo', Piero Luigi; Perrone, Dr; Lombardi, G.. - In: ANTICANCER RESEARCH. - ISSN 0250-7005. - 24:6(2004), pp. 4169-4174.
Fatty Acid Synthase (FAS) is a Marker of Increased Risk of Recurrence in Lung Carcinoma
ALO', Piero Luigi;
2004
Abstract
.Background: We explored the expression of Fatty Acid Synthase (FAS) in lung carcinomas and its association with clinico-pathological features and prognosis. FAS is a recently discovered molecule involved in the energy supply of normal cells. FAS is also overexpressed in neoplastic tissues because of their increased necessity for energy. Patients and Methods: One hundred and six patients with non-small cell lung carcinoma were followed-up for an average period of 5 years. FAS expression was detected immunohistochemically. Results: FAS staining was observed in 61 out of 106 cases (57.54%). Statistical analysis revealed that FAS had an overall low prognostic value (p=0.14), while FAS-negative expression in stage I patients showed a trend for better survival (p=0.10). PTNM stage (p0.0001) was the only significant prognostic marker for overall survival. Conclusion: FAS is a reliable marker of low-stage clinically aggressive lung carcinomas. The determination of FAS expression in lung carcinomas may stratify patients and determine therapeutic approaches for their care. Note .I documenti in IRIS sono protetti da copyright e tutti i diritti sono riservati, salvo diversa indicazione.
